The global market for Spinal Muscular Atrophy Medicine was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Spinal Muscular Atrophy Medicine, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Spinal Muscular Atrophy Medicine by region & country, by Type, and by Application.

The Spinal Muscular Atrophy Medicine market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Spinal Muscular Atrophy Medicine.

Market Segmentation

Scope of Spinal Muscular Atrophy Medicine - Market Report

Report Metric	Details
Report Name	Spinal Muscular Atrophy Medicine - Market
CAGR	5%
Segment by Type:	LMI-070 ND-602 NT-1654 Nusinersen NXD-30001 Others
Segment by Application	Hospital Clinic Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Astellas Pharma Inc., AveXis, Inc., Bioblast Pharma Ltd., Cytokinetics, Inc. 24, F. Hoffmann-La Roche Ltd., Genethon, Genzyme Corporation, GMP-Orphan SAS, Ionis Pharmaceuticals, Inc., Longevity Biotech, Inc, Neurodyn Inc., Neurotune AG, Novartis AG, Sarepta Therapeutics, Inc., Voyager Therapeutics, Inc., Vybion, Inc., WAVE Life Sciences Ltd.
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Spinal Muscular Atrophy Medicine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Spinal Muscular Atrophy Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Spinal Muscular Atrophy Medicine in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

Who are the main players in the Spinal Muscular Atrophy Medicine - Market report?

Ans: The main players in the Spinal Muscular Atrophy Medicine - Market are Astellas Pharma Inc., AveXis, Inc., Bioblast Pharma Ltd., Cytokinetics, Inc. 24, F. Hoffmann-La Roche Ltd., Genethon, Genzyme Corporation, GMP-Orphan SAS, Ionis Pharmaceuticals, Inc., Longevity Biotech, Inc, Neurodyn Inc., Neurotune AG, Novartis AG, Sarepta Therapeutics, Inc., Voyager Therapeutics, Inc., Vybion, Inc., WAVE Life Sciences Ltd.

What are the Application segmentation covered in the Spinal Muscular Atrophy Medicine - Market report?

Ans: The Applications covered in the Spinal Muscular Atrophy Medicine - Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Spinal Muscular Atrophy Medicine - Market report?

Ans: The Types covered in the Spinal Muscular Atrophy Medicine - Market report are LMI-070, ND-602, NT-1654, Nusinersen, NXD-30001, Others

1 Market Overview

1.1 Spinal Muscular Atrophy Medicine Product Introduction

1.2 Global Spinal Muscular Atrophy Medicine Market Size Forecast

1.2.1 Global Spinal Muscular Atrophy Medicine Sales Value (2019-2030)

1.2.2 Global Spinal Muscular Atrophy Medicine Sales Volume (2019-2030)

1.2.3 Global Spinal Muscular Atrophy Medicine Sales Price (2019-2030)

1.3 Spinal Muscular Atrophy Medicine Market Trends & Drivers

1.3.1 Spinal Muscular Atrophy Medicine Industry Trends

1.3.2 Spinal Muscular Atrophy Medicine Market Drivers & Opportunity

1.3.3 Spinal Muscular Atrophy Medicine Market Challenges

1.3.4 Spinal Muscular Atrophy Medicine Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Spinal Muscular Atrophy Medicine Players Revenue Ranking (2023)

2.2 Global Spinal Muscular Atrophy Medicine Revenue by Company (2019-2024)

2.3 Global Spinal Muscular Atrophy Medicine Players Sales Volume Ranking (2023)

2.4 Global Spinal Muscular Atrophy Medicine Sales Volume by Company Players (2019-2024)

2.5 Global Spinal Muscular Atrophy Medicine Average Price by Company (2019-2024)

2.6 Key Manufacturers Spinal Muscular Atrophy Medicine Manufacturing Base Distribution and Headquarters

2.7 Key Manufacturers Spinal Muscular Atrophy Medicine Product Offered

2.8 Key Manufacturers Time to Begin Mass Production of Spinal Muscular Atrophy Medicine

2.9 Spinal Muscular Atrophy Medicine Market Competitive Analysis

2.9.1 Spinal Muscular Atrophy Medicine Market Concentration Rate (2019-2024)

2.9.2 Global 5 and 10 Largest Manufacturers by Spinal Muscular Atrophy Medicine Revenue in 2023

2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Spinal Muscular Atrophy Medicine as of 2023)

2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 LMI-070

3.1.2 ND-602

3.1.3 NT-1654

3.1.4 Nusinersen

3.1.5 NXD-30001

3.1.6 Others

3.2 Global Spinal Muscular Atrophy Medicine Sales Value by Type

3.2.1 Global Spinal Muscular Atrophy Medicine Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Spinal Muscular Atrophy Medicine Sales Value, by Type (2019-2030)

3.2.3 Global Spinal Muscular Atrophy Medicine Sales Value, by Type (%) (2019-2030)

3.3 Global Spinal Muscular Atrophy Medicine Sales Volume by Type

3.3.1 Global Spinal Muscular Atrophy Medicine Sales Volume by Type (2019 VS 2023 VS 2030)

3.3.2 Global Spinal Muscular Atrophy Medicine Sales Volume, by Type (2019-2030)

3.3.3 Global Spinal Muscular Atrophy Medicine Sales Volume, by Type (%) (2019-2030)

3.4 Global Spinal Muscular Atrophy Medicine Average Price by Type (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hospital

4.1.2 Clinic

4.1.3 Others

4.2 Global Spinal Muscular Atrophy Medicine Sales Value by Application

4.2.1 Global Spinal Muscular Atrophy Medicine Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Spinal Muscular Atrophy Medicine Sales Value, by Application (2019-2030)

4.2.3 Global Spinal Muscular Atrophy Medicine Sales Value, by Application (%) (2019-2030)

4.3 Global Spinal Muscular Atrophy Medicine Sales Volume by Application

4.3.1 Global Spinal Muscular Atrophy Medicine Sales Volume by Application (2019 VS 2023 VS 2030)

4.3.2 Global Spinal Muscular Atrophy Medicine Sales Volume, by Application (2019-2030)

4.3.3 Global Spinal Muscular Atrophy Medicine Sales Volume, by Application (%) (2019-2030)

4.4 Global Spinal Muscular Atrophy Medicine Average Price by Application (2019-2030)

5 Segmentation by Region

5.1 Global Spinal Muscular Atrophy Medicine Sales Value by Region

5.1.1 Global Spinal Muscular Atrophy Medicine Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Spinal Muscular Atrophy Medicine Sales Value by Region (2019-2024)

5.1.3 Global Spinal Muscular Atrophy Medicine Sales Value by Region (2025-2030)

5.1.4 Global Spinal Muscular Atrophy Medicine Sales Value by Region (%), (2019-2030)

5.2 Global Spinal Muscular Atrophy Medicine Sales Volume by Region

5.2.1 Global Spinal Muscular Atrophy Medicine Sales Volume by Region: 2019 VS 2023 VS 2030

5.2.2 Global Spinal Muscular Atrophy Medicine Sales Volume by Region (2019-2024)

5.2.3 Global Spinal Muscular Atrophy Medicine Sales Volume by Region (2025-2030)

5.2.4 Global Spinal Muscular Atrophy Medicine Sales Volume by Region (%), (2019-2030)

5.3 Global Spinal Muscular Atrophy Medicine Average Price by Region (2019-2030)

5.4 North America

5.4.1 North America Spinal Muscular Atrophy Medicine Sales Value, 2019-2030

5.4.2 North America Spinal Muscular Atrophy Medicine Sales Value by Country (%), 2023 VS 2030

5.5 Europe

5.5.1 Europe Spinal Muscular Atrophy Medicine Sales Value, 2019-2030

5.5.2 Europe Spinal Muscular Atrophy Medicine Sales Value by Country (%), 2023 VS 2030

5.6 Asia Pacific

5.6.1 Asia Pacific Spinal Muscular Atrophy Medicine Sales Value, 2019-2030

5.6.2 Asia Pacific Spinal Muscular Atrophy Medicine Sales Value by Country (%), 2023 VS 2030

5.7 South America

5.7.1 South America Spinal Muscular Atrophy Medicine Sales Value, 2019-2030

5.7.2 South America Spinal Muscular Atrophy Medicine Sales Value by Country (%), 2023 VS 2030

5.8 Middle East & Africa

5.8.1 Middle East & Africa Spinal Muscular Atrophy Medicine Sales Value, 2019-2030

5.8.2 Middle East & Africa Spinal Muscular Atrophy Medicine Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Spinal Muscular Atrophy Medicine Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Spinal Muscular Atrophy Medicine Sales Value

6.2.1 Key Countries/Regions Spinal Muscular Atrophy Medicine Sales Value, 2019-2030

6.2.2 Key Countries/Regions Spinal Muscular Atrophy Medicine Sales Volume, 2019-2030

6.3 United States

6.3.1 United States Spinal Muscular Atrophy Medicine Sales Value, 2019-2030

6.3.2 United States Spinal Muscular Atrophy Medicine Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Spinal Muscular Atrophy Medicine Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Spinal Muscular Atrophy Medicine Sales Value, 2019-2030

6.4.2 Europe Spinal Muscular Atrophy Medicine Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Spinal Muscular Atrophy Medicine Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Spinal Muscular Atrophy Medicine Sales Value, 2019-2030

6.5.2 China Spinal Muscular Atrophy Medicine Sales Value by Type (%), 2023 VS 2030

6.5.3 China Spinal Muscular Atrophy Medicine Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Spinal Muscular Atrophy Medicine Sales Value, 2019-2030

6.6.2 Japan Spinal Muscular Atrophy Medicine Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Spinal Muscular Atrophy Medicine Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Spinal Muscular Atrophy Medicine Sales Value, 2019-2030

6.7.2 South Korea Spinal Muscular Atrophy Medicine Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Spinal Muscular Atrophy Medicine Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Spinal Muscular Atrophy Medicine Sales Value, 2019-2030

6.8.2 Southeast Asia Spinal Muscular Atrophy Medicine Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Spinal Muscular Atrophy Medicine Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Spinal Muscular Atrophy Medicine Sales Value, 2019-2030

6.9.2 India Spinal Muscular Atrophy Medicine Sales Value by Type (%), 2023 VS 2030

6.9.3 India Spinal Muscular Atrophy Medicine Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Astellas Pharma Inc.

7.1.1 Astellas Pharma Inc. Company Information

7.1.2 Astellas Pharma Inc. Introduction and Business Overview

7.1.3 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2019-2024)

7.1.4 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Offerings

7.1.5 Astellas Pharma Inc. Recent Development

7.2 AveXis, Inc.

7.2.1 AveXis, Inc. Company Information

7.2.2 AveXis, Inc. Introduction and Business Overview

7.2.3 AveXis, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2019-2024)

7.2.4 AveXis, Inc. Spinal Muscular Atrophy Medicine Product Offerings

7.2.5 AveXis, Inc. Recent Development

7.3 Bioblast Pharma Ltd.

7.3.1 Bioblast Pharma Ltd. Company Information

7.3.2 Bioblast Pharma Ltd. Introduction and Business Overview

7.3.3 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2019-2024)

7.3.4 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Offerings

7.3.5 Bioblast Pharma Ltd. Recent Development

7.4 Cytokinetics, Inc. 24

7.4.1 Cytokinetics, Inc. 24 Company Information

7.4.2 Cytokinetics, Inc. 24 Introduction and Business Overview

7.4.3 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2019-2024)

7.4.4 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product Offerings

7.4.5 Cytokinetics, Inc. 24 Recent Development

7.5 F. Hoffmann-La Roche Ltd.

7.5.1 F. Hoffmann-La Roche Ltd. Company Information

7.5.2 F. Hoffmann-La Roche Ltd. Introduction and Business Overview

7.5.3 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2019-2024)

7.5.4 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Offerings

7.5.5 F. Hoffmann-La Roche Ltd. Recent Development

7.6 Genethon

7.6.1 Genethon Company Information

7.6.2 Genethon Introduction and Business Overview

7.6.3 Genethon Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2019-2024)

7.6.4 Genethon Spinal Muscular Atrophy Medicine Product Offerings

7.6.5 Genethon Recent Development

7.7 Genzyme Corporation

7.7.1 Genzyme Corporation Company Information

7.7.2 Genzyme Corporation Introduction and Business Overview

7.7.3 Genzyme Corporation Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2019-2024)

7.7.4 Genzyme Corporation Spinal Muscular Atrophy Medicine Product Offerings

7.7.5 Genzyme Corporation Recent Development

7.8 GMP-Orphan SAS

7.8.1 GMP-Orphan SAS Company Information

7.8.2 GMP-Orphan SAS Introduction and Business Overview

7.8.3 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2019-2024)

7.8.4 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Offerings

7.8.5 GMP-Orphan SAS Recent Development

7.9 Ionis Pharmaceuticals, Inc.

7.9.1 Ionis Pharmaceuticals, Inc. Company Information

7.9.2 Ionis Pharmaceuticals, Inc. Introduction and Business Overview

7.9.3 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2019-2024)

7.9.4 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product Offerings

7.9.5 Ionis Pharmaceuticals, Inc. Recent Development

7.10 Longevity Biotech, Inc

7.10.1 Longevity Biotech, Inc Company Information

7.10.2 Longevity Biotech, Inc Introduction and Business Overview

7.10.3 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2019-2024)

7.10.4 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product Offerings

7.10.5 Longevity Biotech, Inc Recent Development

7.11 Neurodyn Inc.

7.11.1 Neurodyn Inc. Company Information

7.11.2 Neurodyn Inc. Introduction and Business Overview

7.11.3 Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2019-2024)

7.11.4 Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Offerings

7.11.5 Neurodyn Inc. Recent Development

7.12 Neurotune AG

7.12.1 Neurotune AG Company Information

7.12.2 Neurotune AG Introduction and Business Overview

7.12.3 Neurotune AG Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2019-2024)

7.12.4 Neurotune AG Spinal Muscular Atrophy Medicine Product Offerings

7.12.5 Neurotune AG Recent Development

7.13 Novartis AG

7.13.1 Novartis AG Company Information

7.13.2 Novartis AG Introduction and Business Overview

7.13.3 Novartis AG Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2019-2024)

7.13.4 Novartis AG Spinal Muscular Atrophy Medicine Product Offerings

7.13.5 Novartis AG Recent Development

7.14 Sarepta Therapeutics, Inc.

7.14.1 Sarepta Therapeutics, Inc. Company Information

7.14.2 Sarepta Therapeutics, Inc. Introduction and Business Overview

7.14.3 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2019-2024)

7.14.4 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Offerings

7.14.5 Sarepta Therapeutics, Inc. Recent Development

7.15 Voyager Therapeutics, Inc.

7.15.1 Voyager Therapeutics, Inc. Company Information

7.15.2 Voyager Therapeutics, Inc. Introduction and Business Overview

7.15.3 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2019-2024)

7.15.4 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Offerings

7.15.5 Voyager Therapeutics, Inc. Recent Development

7.16 Vybion, Inc.

7.16.1 Vybion, Inc. Company Information

7.16.2 Vybion, Inc. Introduction and Business Overview

7.16.3 Vybion, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2019-2024)

7.16.4 Vybion, Inc. Spinal Muscular Atrophy Medicine Product Offerings

7.16.5 Vybion, Inc. Recent Development

7.17 WAVE Life Sciences Ltd.

7.17.1 WAVE Life Sciences Ltd. Company Information

7.17.2 WAVE Life Sciences Ltd. Introduction and Business Overview

7.17.3 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2019-2024)

7.17.4 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Offerings

7.17.5 WAVE Life Sciences Ltd. Recent Development

8 Industry Chain Analysis

8.1 Spinal Muscular Atrophy Medicine Industrial Chain

8.2 Spinal Muscular Atrophy Medicine Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Spinal Muscular Atrophy Medicine Sales Model

8.5.2 Sales Channel

8.5.3 Spinal Muscular Atrophy Medicine Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Astellas Pharma Inc

Avexis

Bioblast Pharma Ltd.

Cytokinetics, Inc. 24

F Hoffmann La Roche Ltd

Genethon

Genzyme Corporation

GMP-Orphan SAS

Ionis Pharmaceuticals Inc

Longevity Biotech Inc

Neurodyn Inc.

Neurotune AG

Novartis

Sarepta Therapeutics Inc

Voyager Therapeutics Inc

Vybion

WAVE Life Sciences Ltd

List of Tables

Table 1. Spinal Muscular Atrophy Medicine Market Trends

Table 2. Spinal Muscular Atrophy Medicine Market Drivers & Opportunity

Table 3. Spinal Muscular Atrophy Medicine Market Challenges

Table 4. Spinal Muscular Atrophy Medicine Market Restraints

Table 5. Global Spinal Muscular Atrophy Medicine Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Company (2019-2024)

Table 7. Global Spinal Muscular Atrophy Medicine Sales Volume by Company (2019-2024) & (K Pcs)

Table 8. Global Spinal Muscular Atrophy Medicine Sales Volume Market Share by Company (2019-2024)

Table 9. Global Market Spinal Muscular Atrophy Medicine Price by Company (2019-2024) & (USD/Pcs)

Table 10. Key Manufacturers Spinal Muscular Atrophy Medicine Manufacturing Base Distribution and Headquarters

Table 11. Key Manufacturers Spinal Muscular Atrophy Medicine Product Type

Table 12. Key Manufacturers Time to Begin Mass Production of Spinal Muscular Atrophy Medicine

Table 13. Global Spinal Muscular Atrophy Medicine Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Spinal Muscular Atrophy Medicine as of 2023)

Table 15. Mergers & Acquisitions, Expansion Plans

Table 16. Global Spinal Muscular Atrophy Medicine Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 17. Global Spinal Muscular Atrophy Medicine Sales Value by Type (2019-2024) & (US$ Million)

Table 18. Global Spinal Muscular Atrophy Medicine Sales Value by Type (2025-2030) & (US$ Million)

Table 19. Global Spinal Muscular Atrophy Medicine Sales Market Share in Value by Type (2019-2024) & (%)

Table 20. Global Spinal Muscular Atrophy Medicine Sales Market Share in Value by Type (2025-2030) & (%)

Table 21. Global Spinal Muscular Atrophy Medicine Sales Volume by Type: 2019 VS 2023 VS 2030 (K Pcs)

Table 22. Global Spinal Muscular Atrophy Medicine Sales Volume by Type (2019-2024) & (K Pcs)

Table 23. Global Spinal Muscular Atrophy Medicine Sales Volume by Type (2025-2030) & (K Pcs)

Table 24. Global Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Type (2019-2024) & (%)

Table 25. Global Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Type (2025-2030) & (%)

Table 26. Global Spinal Muscular Atrophy Medicine Price by Type (2019-2024) & (USD/Pcs)

Table 27. Global Spinal Muscular Atrophy Medicine Price by Type (2025-2030) & (USD/Pcs)

Table 28. Global Spinal Muscular Atrophy Medicine Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 29. Global Spinal Muscular Atrophy Medicine Sales Value by Application (2019-2024) & (US$ Million)

Table 30. Global Spinal Muscular Atrophy Medicine Sales Value by Application (2025-2030) & (US$ Million)

Table 31. Global Spinal Muscular Atrophy Medicine Sales Market Share in Value by Application (2019-2024) & (%)

Table 32. Global Spinal Muscular Atrophy Medicine Sales Market Share in Value by Application (2025-2030) & (%)

Table 33. Global Spinal Muscular Atrophy Medicine Sales Volume by Application: 2019 VS 2023 VS 2030 (K Pcs)

Table 34. Global Spinal Muscular Atrophy Medicine Sales Volume by Application (2019-2024) & (K Pcs)

Table 35. Global Spinal Muscular Atrophy Medicine Sales Volume by Application (2025-2030) & (K Pcs)

Table 36. Global Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Application (2019-2024) & (%)

Table 37. Global Spinal Muscular Atrophy Medicine Sales Market Share in Volume by Application (2025-2030) & (%)

Table 38. Global Spinal Muscular Atrophy Medicine Price by Application (2019-2024) & (USD/Pcs)

Table 39. Global Spinal Muscular Atrophy Medicine Price by Application (2025-2030) & (USD/Pcs)

Table 40. Global Spinal Muscular Atrophy Medicine Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Global Spinal Muscular Atrophy Medicine Sales Value by Region (2019-2024) & (US$ Million)

Table 42. Global Spinal Muscular Atrophy Medicine Sales Value by Region (2025-2030) & (US$ Million)

Table 43. Global Spinal Muscular Atrophy Medicine Sales Value by Region (2019-2024) & (%)

Table 44. Global Spinal Muscular Atrophy Medicine Sales Value by Region (2025-2030) & (%)

Table 45. Global Spinal Muscular Atrophy Medicine Sales Volume by Region (K Pcs): 2019 VS 2023 VS 2030

Table 46. Global Spinal Muscular Atrophy Medicine Sales Volume by Region (2019-2024) & (K Pcs)

Table 47. Global Spinal Muscular Atrophy Medicine Sales Volume by Region (2025-2030) & (K Pcs)

Table 48. Global Spinal Muscular Atrophy Medicine Sales Volume by Region (2019-2024) & (%)

Table 49. Global Spinal Muscular Atrophy Medicine Sales Volume by Region (2025-2030) & (%)

Table 50. Global Spinal Muscular Atrophy Medicine Average Price by Region (2019-2024) & (USD/Pcs)

Table 51. Global Spinal Muscular Atrophy Medicine Average Price by Region (2025-2030) & (USD/Pcs)

Table 52. Key Countries/Regions Spinal Muscular Atrophy Medicine Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 53. Key Countries/Regions Spinal Muscular Atrophy Medicine Sales Value, (2019-2024) & (US$ Million)

Table 54. Key Countries/Regions Spinal Muscular Atrophy Medicine Sales Value, (2025-2030) & (US$ Million)

Table 55. Key Countries/Regions Spinal Muscular Atrophy Medicine Sales Volume, (2019-2024) & (K Pcs)

Table 56. Key Countries/Regions Spinal Muscular Atrophy Medicine Sales Volume, (2025-2030) & (K Pcs)

Table 57. Astellas Pharma Inc. Company Information

Table 58. Astellas Pharma Inc. Introduction and Business Overview

Table 59. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 60. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Offerings

Table 61. Astellas Pharma Inc. Recent Development

Table 62. AveXis, Inc. Company Information

Table 63. AveXis, Inc. Introduction and Business Overview

Table 64. AveXis, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 65. AveXis, Inc. Spinal Muscular Atrophy Medicine Product Offerings

Table 66. AveXis, Inc. Recent Development

Table 67. Bioblast Pharma Ltd. Company Information

Table 68. Bioblast Pharma Ltd. Introduction and Business Overview

Table 69. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 70. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Offerings

Table 71. Bioblast Pharma Ltd. Recent Development

Table 72. Cytokinetics, Inc. 24 Company Information

Table 73. Cytokinetics, Inc. 24 Introduction and Business Overview

Table 74. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 75. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product Offerings

Table 76. Cytokinetics, Inc. 24 Recent Development

Table 77. F. Hoffmann-La Roche Ltd. Company Information

Table 78. F. Hoffmann-La Roche Ltd. Introduction and Business Overview

Table 79. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 80. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Offerings

Table 81. F. Hoffmann-La Roche Ltd. Recent Development

Table 82. Genethon Company Information

Table 83. Genethon Introduction and Business Overview

Table 84. Genethon Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 85. Genethon Spinal Muscular Atrophy Medicine Product Offerings

Table 86. Genethon Recent Development

Table 87. Genzyme Corporation Company Information

Table 88. Genzyme Corporation Introduction and Business Overview

Table 89. Genzyme Corporation Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 90. Genzyme Corporation Spinal Muscular Atrophy Medicine Product Offerings

Table 91. Genzyme Corporation Recent Development

Table 92. GMP-Orphan SAS Company Information

Table 93. GMP-Orphan SAS Introduction and Business Overview

Table 94. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 95. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Offerings

Table 96. GMP-Orphan SAS Recent Development

Table 97. Ionis Pharmaceuticals, Inc. Company Information

Table 98. Ionis Pharmaceuticals, Inc. Introduction and Business Overview

Table 99. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 100. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product Offerings

Table 101. Ionis Pharmaceuticals, Inc. Recent Development

Table 102. Longevity Biotech, Inc Company Information

Table 103. Longevity Biotech, Inc Introduction and Business Overview

Table 104. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 105. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product Offerings

Table 106. Longevity Biotech, Inc Recent Development

Table 107. Neurodyn Inc. Company Information

Table 108. Neurodyn Inc. Introduction and Business Overview

Table 109. Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 110. Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Offerings

Table 111. Neurodyn Inc. Recent Development

Table 112. Neurotune AG Company Information

Table 113. Neurotune AG Introduction and Business Overview

Table 114. Neurotune AG Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 115. Neurotune AG Spinal Muscular Atrophy Medicine Product Offerings

Table 116. Neurotune AG Recent Development

Table 117. Novartis AG Company Information

Table 118. Novartis AG Introduction and Business Overview

Table 119. Novartis AG Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 120. Novartis AG Spinal Muscular Atrophy Medicine Product Offerings

Table 121. Novartis AG Recent Development

Table 122. Sarepta Therapeutics, Inc. Company Information

Table 123. Sarepta Therapeutics, Inc. Introduction and Business Overview

Table 124. Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 125. Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Offerings

Table 126. Sarepta Therapeutics, Inc. Recent Development

Table 127. Voyager Therapeutics, Inc. Company Information

Table 128. Voyager Therapeutics, Inc. Introduction and Business Overview

Table 129. Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 130. Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Offerings

Table 131. Voyager Therapeutics, Inc. Recent Development

Table 132. Vybion, Inc. Company Information

Table 133. Vybion, Inc. Introduction and Business Overview

Table 134. Vybion, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 135. Vybion, Inc. Spinal Muscular Atrophy Medicine Product Offerings

Table 136. Vybion, Inc. Recent Development

Table 137. WAVE Life Sciences Ltd. Company Information

Table 138. WAVE Life Sciences Ltd. Introduction and Business Overview

Table 139. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 140. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Offerings

Table 141. WAVE Life Sciences Ltd. Recent Development

Table 142. Key Raw Materials Lists

Table 143. Raw Materials Key Suppliers Lists

Table 144. Spinal Muscular Atrophy Medicine Downstream Customers

Table 145. Spinal Muscular Atrophy Medicine Distributors List

Table 146. Research Programs/Design for This Report

Table 147. Key Data Information from Secondary Sources

Table 148. Key Data Information from Primary Sources

List of Figures

Figure 1. Spinal Muscular Atrophy Medicine Product Picture

Figure 2. Global Spinal Muscular Atrophy Medicine Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Spinal Muscular Atrophy Medicine Sales Value (2019-2030) & (US$ Million)

Figure 4. Global Spinal Muscular Atrophy Medicine Sales Volume (2019-2030) & (K Pcs)

Figure 5. Global Spinal Muscular Atrophy Medicine Sales Price (2019-2030) & (USD/Pcs)

Figure 6. Spinal Muscular Atrophy Medicine Report Years Considered

Figure 7. Global Spinal Muscular Atrophy Medicine Players Revenue Ranking (2023) & (US$ Million)

Figure 8. Global Spinal Muscular Atrophy Medicine Players Sales Volume Ranking (2023) & (K Pcs)

Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Spinal Muscular Atrophy Medicine Revenue in 2023

Figure 10. Spinal Muscular Atrophy Medicine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 11. LMI-070 Picture

Figure 12. ND-602 Picture

Figure 13. NT-1654 Picture

Figure 14. Nusinersen Picture

Figure 15. NXD-30001 Picture

Figure 16. Others Picture

Figure 17. Global Spinal Muscular Atrophy Medicine Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 18. Global Spinal Muscular Atrophy Medicine Sales Value Market Share by Type, 2023 & 2030

Figure 19. Global Spinal Muscular Atrophy Medicine Sales Volume by Type (2019 VS 2023 VS 2030) & (K Pcs)

Figure 20. Global Spinal Muscular Atrophy Medicine Sales Volume Market Share by Type, 2023 & 2030

Figure 21. Global Spinal Muscular Atrophy Medicine Price by Type (2019-2030) & (USD/Pcs)

Figure 22. Product Picture of Hospital

Figure 23. Product Picture of Clinic

Figure 24. Product Picture of Others

Figure 25. Global Spinal Muscular Atrophy Medicine Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 26. Global Spinal Muscular Atrophy Medicine Sales Value Market Share by Application, 2023 & 2030

Figure 27. Global Spinal Muscular Atrophy Medicine Sales Volume by Application (2019 VS 2023 VS 2030) & (K Pcs)

Figure 28. Global Spinal Muscular Atrophy Medicine Sales Volume Market Share by Application, 2023 & 2030

Figure 29. Global Spinal Muscular Atrophy Medicine Price by Application (2019-2030) & (USD/Pcs)

Figure 30. North America Spinal Muscular Atrophy Medicine Sales Value (2019-2030) & (US$ Million)

Figure 31. North America Spinal Muscular Atrophy Medicine Sales Value by Country (%), 2023 VS 2030

Figure 32. Europe Spinal Muscular Atrophy Medicine Sales Value (2019-2030) & (US$ Million)

Figure 33. Europe Spinal Muscular Atrophy Medicine Sales Value by Country (%), 2023 VS 2030

Figure 34. Asia Pacific Spinal Muscular Atrophy Medicine Sales Value (2019-2030) & (US$ Million)

Figure 35. Asia Pacific Spinal Muscular Atrophy Medicine Sales Value by Country (%), 2023 VS 2030

Figure 36. South America Spinal Muscular Atrophy Medicine Sales Value (2019-2030) & (US$ Million)

Figure 37. South America Spinal Muscular Atrophy Medicine Sales Value by Country (%), 2023 VS 2030

Figure 38. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Value (2019-2030) & (US$ Million)

Figure 39. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Value by Country (%), 2023 VS 2030

Figure 40. Key Countries/Regions Spinal Muscular Atrophy Medicine Sales Value (%), (2019-2030)

Figure 41. Key Countries/Regions Spinal Muscular Atrophy Medicine Sales Volume (%), (2019-2030)

Figure 42. United States Spinal Muscular Atrophy Medicine Sales Value, (2019-2030) & (US$ Million)

Figure 43. United States Spinal Muscular Atrophy Medicine Sales Value by Type (%), 2023 VS 2030

Figure 44. United States Spinal Muscular Atrophy Medicine Sales Value by Application (%), 2023 VS 2030

Figure 45. Europe Spinal Muscular Atrophy Medicine Sales Value, (2019-2030) & (US$ Million)

Figure 46. Europe Spinal Muscular Atrophy Medicine Sales Value by Type (%), 2023 VS 2030

Figure 47. Europe Spinal Muscular Atrophy Medicine Sales Value by Application (%), 2023 VS 2030

Figure 48. China Spinal Muscular Atrophy Medicine Sales Value, (2019-2030) & (US$ Million)

Figure 49. China Spinal Muscular Atrophy Medicine Sales Value by Type (%), 2023 VS 2030

Figure 50. China Spinal Muscular Atrophy Medicine Sales Value by Application (%), 2023 VS 2030

Figure 51. Japan Spinal Muscular Atrophy Medicine Sales Value, (2019-2030) & (US$ Million)

Figure 52. Japan Spinal Muscular Atrophy Medicine Sales Value by Type (%), 2023 VS 2030

Figure 53. Japan Spinal Muscular Atrophy Medicine Sales Value by Application (%), 2023 VS 2030

Figure 54. South Korea Spinal Muscular Atrophy Medicine Sales Value, (2019-2030) & (US$ Million)

Figure 55. South Korea Spinal Muscular Atrophy Medicine Sales Value by Type (%), 2023 VS 2030

Figure 56. South Korea Spinal Muscular Atrophy Medicine Sales Value by Application (%), 2023 VS 2030

Figure 57. Southeast Asia Spinal Muscular Atrophy Medicine Sales Value, (2019-2030) & (US$ Million)

Figure 58. Southeast Asia Spinal Muscular Atrophy Medicine Sales Value by Type (%), 2023 VS 2030

Figure 59. Southeast Asia Spinal Muscular Atrophy Medicine Sales Value by Application (%), 2023 VS 2030

Figure 60. India Spinal Muscular Atrophy Medicine Sales Value, (2019-2030) & (US$ Million)

Figure 61. India Spinal Muscular Atrophy Medicine Sales Value by Type (%), 2023 VS 2030

Figure 62. India Spinal Muscular Atrophy Medicine Sales Value by Application (%), 2023 VS 2030

Figure 63. Spinal Muscular Atrophy Medicine Industrial Chain

Figure 64. Spinal Muscular Atrophy Medicine Manufacturing Cost Structure

Figure 65. Channels of Distribution (Direct Sales, and Distribution)

Figure 66. Bottom-up and Top-down Approaches for This Report

Figure 67. Data Triangulation

Figure 68. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions